Novavax, Inc (NASDAQ: NVAX) announced Friday it has reached terms with the government of the United Kingdom to supply 60 million doses of its COVID-19 vaccine, subject to success of pending clinical trials.
The Maryland-based company will supply the U.K. with its NVX-CoV2373 vaccine for an undisclosed amount. In turn, the U.K. government will support the drug’s Phase 3 human trials in the country, the biotechnology company said in a statement.
Novavax is also expanding its collaboration with Fujifilm Holdings Corporation (OTC: FUJIF) unit FUJIFILM Diosynth Biotechnologies, which will manufacture the antigen for the vaccine at its Stockton-on-Tees facility in the U.K., as well as in North Carolina and Texas.
Global efforts to secure vaccines have begun to make headway. Last month, the U.K. inked a deal with GlaxoSmithKline plc (NYSE: GSK) and Sanofi SA (NYSE: SNY) to supply it with 60 million doses of COVID-19 vaccine.
Indian vaccine maker Serum Institute Of India Pvt. Ltd. reached a deal with AstraZeneca and Novavax to supply their COVID-19 vaccines to middle and low-income countries this month.
Russia meanwhile claims its “Sputnik V” vaccine is safe for immediate use, although experts disagree on whether it has gone through all the necessary trials.
Novavax shares closed nearly 7.1% higher at $133.28 on Thursday and rose almost 1.7% in the after-hours session.
See more from Benzinga
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.